Longitudinal Changes in Alemtuzumab ADAs in Humans
A study enrolled 15 participants to observe changes in anti-drug antibodies (ADAs) after treatment with alemtuzumab over a two-year follow-up. However, no results or outcomes have been posted, and the planned endpoints do not provide evidence on their own.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Not reported
Why it matters
Understanding ADAs is crucial as they can affect the efficacy and safety of alemtuzumab treatment. This knowledge could inform future studies and treatment approaches in MS.
What this does not prove
The study has no reported findings, making it impossible to assess efficacy, safety, or outcomes. The details on planned endpoints do not constitute results.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 15 · actual enrolment
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Trial registrationADAs to Alemtuzumab ↗
Supporting passages (10)
study designStudy type: Observational
sample sizeEnrollment: 15 participants (actual)
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
limitationsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
peer reviewedTrial registry record.
subjectsParticipants: people; ages from 18 Years to 55 Years; sex All
primary endpointPrimary endpoints: To quantify the longitudinal changes in alemtuzumab ADAs
interventionInterventions: Alemtuzumab
follow upFollow-up: 2 years; 1 year
sample size basisEnrollment: 15 participants (actual)
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.